Usefulness of 18F-NaF PET/CT for bone metastasis

Usefulness of 18F-NaF PET/CT for bone metastasis - 18F-NaF for bone metastasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026275

Enrollment

Registered

2017-02-28

Start date

2017-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone metastasis

Interventions

Injection of PET tracer One injection for one exam Radiation dose is under 370 MBq for one exam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosed as bone metastasis 2) Regardless of sex 3) informed consent is available

Exclusion criteria

Exclusion criteria: 1) Who have already undergone radiotherapy or surgical treatment for bone metastasis 2) Poor condition (i.e. Performance status 3 or 4) 3) Those who is breastfeeding, pregnant or wish for pregnancy 4) Those who is thought to be inappropriate by researcher

Design outcomes

Primary

Measure	Time frame
Effectiveness of 18F-NaF PET for determining of predicting the effect of bone metastasis treatment.	—

Secondary

Measure	Time frame
Effectiveness of 18F-NaF PET for detecting bone metastasis.	—

Countries

Japan

Contacts

Public ContactYoshiyuki Kitamura

Graduate School of Medical Science, Kyushu University Department of Clinical Radiology

ykita@radiol.med.kyushu-u.ac.jp092-641-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026